Translation of Targeted Radiation Sensitizers into Clinical Trials
- 1 October 2016
- journal article
- review article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 26 (4) , 261-270
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistanceBlood Cancer Journal, 2013
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiationCell Death & Disease, 2012
- Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)Journal of Thoracic Oncology, 2012
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replicationNucleic Acids Research, 2011
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonucleaseJournal of Cell Biology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer CellsPancreas, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- ATR: an essential regulator of genome integrityNature Reviews Molecular Cell Biology, 2008